C6930
Monoclonal Anti-Cytokeratin Peptide 19 antibody produced in mouse
clone A53-B/A2, tissue culture supernatant
Synonym(s):
Anti-CK19, Anti-K19, Anti-K1CS
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
biological source
mouse
conjugate
unconjugated
antibody form
tissue culture supernatant
antibody product type
primary antibodies
clone
A53-B/A2, monoclonal
mol wt
antigen 40 kDa
contains
15 mM sodium azide
species reactivity
human
technique(s)
indirect immunofluorescence: 1:50 using formalin-fixed, paraffin-embedded, human tissue sections
microarray: suitable
isotype
IgG2a
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... KRT19(3880)
General description
Monoclonal Anti-Cytokeratin Peptide 19 (mouse IgG2a isotype) is derived from the A53-B/A2 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with mammary human carcinoma cell line MCF-7. Monoclonal Anti-Cytokeratin Peptide 19, known as clone A53-B/A2, or clone No. Ks 19.1, reacts with the rod domain of human cytokeratin peptide 19 (40 kDa), a cytoskeletal protein restricted to epithelial and carcinoma cells. Cytokeratin 19 is a member of the type I acidic subfamily. It is differentially expressed in various human tissues.
Specificity
Also cited as clone no. KS 19.1, the antibody reacts with the rod domain of cytokeratin peptide 19, a cytoskeletal protein restricted to epithelial and carcinoma cells. Species cross-reactivity is low or absent. The antibody labels simple epithelia and basal cells of non-cornifying stratified squamous epithelia. It is a useful tool in discriminating simple carcinomas from those of different origin and for carcinoma subtyping. This antibody has also been shown to be a marker of pre-malignant lesions of the oral epithelium.
Immunogen
human mammary carcinoma cell line MCF-7.
Application
Monoclonal Anti-Cytokeratin Peptide 19 antibody produced in mouse is also suitable:
- for immunoblotting, for immunocytochemistry,
- for immunofluorescence,
- as a marker of premalignant lesions of the oral epithelium, to label cytokeratin in formalin-fixed or Carnoy-fixed, paraffin embedded tissue and in frozen sections of human tissue, to label simple epithelia and basal cells of noncornifying stratified squamous epithelia.
Monoclonal Anti-Cytokeratin Peptide 19 antibody produced in mouse is suitable for microarray and indirect immunofluorescence at a dilution of 1:50 using formalin-fixed, paraffin-embedded and human tissue sections.
Biochem/physiol Actions
Keratin, type I cytoskeletal 19 (40kDa protein) is also known as cytokeratin-19 (CK-19) or keratin-19 (K19). It is encoded by the KRT19 gene in humans. Keratin 19 is a type I keratin. Keratins are intermediate filament-forming proteins that provide mechanical support and perform a variety of additional functions in epithelial cells. K19 is expressed in a subset of hepatocellular carcinomas (HCC) with poor prognosis and is considered as a biliary/hepatic progenitor cell (HPC) marker. It is also a predictor of poorer prognosis for patients with human lung squamous cell carcinoma (SCC).
Monoclonal anti-cytokeratins are specific markers of epithelial cell differentiation and have been widely used as tools in tumor identification and classification.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
常规特殊物品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Izabela Podgorski et al.
The American journal of pathology, 175(3), 1255-1269 (2009-08-25)
Bone metastasis is a hallmark of advanced prostate and breast cancers, yet the critical factors behind attraction of tumors to the skeleton have not been validated. Here, we investigated the involvement of cathepsin K in the progression of prostate tumors
Minati Satpathy et al.
Theranostics, 9(3), 778-795 (2019-02-28)
Cancer heterogeneity and drug resistance limit the efficacy of cancer therapy. To address this issue, we have developed an integrated treatment protocol for effective treatment of heterogeneous ovarian cancer. Methods: An amphiphilic polymer coated magnetic iron oxide nanoparticle was conjugated
Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles
Satpathy M, et al.
Theranostics, 9(3), 778-778 (2019)
Programmed synthesis of three-dimensional tissues
Todhunter ME, et al.
Nature Methods, 12(10), 975-975 (2015)
Michael E Todhunter et al.
Nature methods, 12(10), 975-981 (2015-09-01)
Reconstituting tissues from their cellular building blocks facilitates the modeling of morphogenesis, homeostasis and disease in vitro. Here we describe DNA-programmed assembly of cells (DPAC), a method to reconstitute the multicellular organization of organoid-like tissues having programmed size, shape, composition
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service